| Year |
Citation |
Score |
| 2020 |
Schmidts A, Marsh LC, Srivastava AA, Bouffard AA, Boroughs AC, Scarfò I, Larson RC, Bedoya F, Choi BD, Frigault MJ, Bailey SR, Leick MB, Vatsa S, Kann MC, Prew MS, et al. Cell-based artificial APC resistant to lentiviral transduction for efficient generation of CAR-T cells from various cell sources. Journal For Immunotherapy of Cancer. 8. PMID 32900862 DOI: 10.1136/Jitc-2020-000990 |
0.469 |
|
| 2019 |
Xu J, Sai H, Li Y, Jordan AC, McGettigan SE, Chen JH, Bedoya F, Fraietta JA, Gladney WL, Melenhorst JJ, Beatty GL. Peripheral blood T cell fitness is diminished in patients with pancreatic carcinoma but can be improved with homeostatic cytokines. Cellular and Molecular Gastroenterology and Hepatology. PMID 31398492 DOI: 10.1016/J.Jcmgh.2019.07.008 |
0.37 |
|
| 2018 |
Ghassemi S, Nunez-Cruz S, O'Connor RS, Fraietta JA, Patel PR, Scholler J, Barrett DM, Lundh SM, Davis MM, Bedoya F, Leferovich J, Lacey SF, Levine BL, Grupp SA, June CH, et al. Reducing Ex Vivo Culture Improves the Anti-leukemic Activity of Chimeric Antigen Receptor (CAR)-T Cells. Cancer Immunology Research. PMID 30030295 DOI: 10.1158/2326-6066.Cir-17-0405 |
0.473 |
|
| 2018 |
Fraietta JA, Lacey SF, Orlando EJ, Pruteanu-Malinici I, Gohil M, Lundh S, Boesteanu AC, Wang Y, O'Connor RS, Hwang WT, Pequignot E, Ambrose DE, Zhang C, Wilcox N, Bedoya F, et al. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nature Medicine. PMID 29713085 DOI: 10.1038/S41591-018-0010-1 |
0.498 |
|
| 2017 |
Ormhøj M, Bedoya F, Frigault MJ, Maus MV. CARs in the Lead Against Multiple Myeloma. Current Hematologic Malignancy Reports. PMID 28233151 DOI: 10.1007/S11899-017-0373-2 |
0.445 |
|
| 2017 |
Bedoya F, Frigault MJ, Maus MV. The Flipside of the Power of Engineered T Cells: Observed and Potential Toxicities of Genetically Modified T Cells as Therapy. Molecular Therapy : the Journal of the American Society of Gene Therapy. 25: 314-320. PMID 28153085 DOI: 10.1016/J.Ymthe.2016.11.011 |
0.428 |
|
| 2017 |
Orlando E, Leary R, Lacey SF, Fraietta J, Bedoya F, Ambrose D, Wilcox N, Maude SL, Frey NV, Levine BL, Grupp SA, Porter DL, Young R, Winckler W, Morrissey M, et al. Gene expression signatures of response to anti-CD19 chimeric antigen receptor (CAR) T-cell therapy in patients with CLL and ALL. Journal of Clinical Oncology. 35: 137-137. DOI: 10.1200/Jco.2017.35.7_Suppl.137 |
0.477 |
|
| 2017 |
Fraietta JA, Lacey SF, Orlando E, Pruteanu J, Gohil M, Wang Y, Boesteanu A, OConnor R, Ambrose DE, Hwang W, Wilcox N, Bedoya F, Dorfmeier C, Chen F, Parakandi H, et al. Identification of Functional Determinants of Response and Resistance to CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy of Chronic Lymphocytic Leukemia Blood. 130: 3181-3181. DOI: 10.1182/Blood.V130.Suppl_1.3181.3181 |
0.485 |
|
| 2016 |
Fraietta JA, Lacey SF, Wilcox NS, Bedoya F, Chen F, Orlando E, Brogdon JL, Hwang W, Frey N, Young RM, Pequignot E, Ambrose DE, Levine BL, Bitter H, Porter DL, et al. Biomarkers of Response to Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy in Patients with Chronic Lymphocytic Leukemia Blood. 128: 57-57. DOI: 10.1182/Blood.V128.22.57.57 |
0.462 |
|
| 2016 |
Ghassemi S, Prachi P, Scholler J, Nunez-Cruz S, Barrett DM, Bedoya F, Fraietta JA, Lacey SF, Levine BL, Grupp SA, June CH, Milone MC, Melenhorst JJ. Minimally Ex Vivo Manipulated Gene-Modified T Cells Display Enhanced Tumor Control Blood. 128: 4549-4549. DOI: 10.1182/Blood.V128.22.4549.4549 |
0.483 |
|
| 2016 |
Jesuraj NJ, Cole JM, Bedoya F, Wells SB, Qin G, Kevlahan S, Maus MV, Ball AJ. A Novel Phase-Change Hydrogel Substrate for T Cell Activation Promotes Increased Expansion of CD8+ Cells Expressing Central Memory and Naive Phenotype Markers Blood. 128: 3368-3368. DOI: 10.1182/Blood.V128.22.3368.3368 |
0.383 |
|
| 2016 |
Ghassemi S, Bedoya F, Nunez-Cruz S, June C, Melenhorst J, Milone M. 203. Shortened T Cell Culture with IL-7 and IL-15 Provides the Most Potent Chimeric Antigen Receptor (CAR)-Modified T Cells for Adoptive Immunotherapy Molecular Therapy. 24: S79. DOI: 10.1016/S1525-0016(16)33012-X |
0.451 |
|
| 2015 |
Melenhorst JJ, Lacey SF, Bedoya F. Chimeric antigen receptor T cells: Self-replicating drugs for cancer. Current Drug Targets. PMID 26302796 DOI: 10.2174/1389450116666150825120427 |
0.361 |
|
| 2015 |
Weissler KA, Garcia V, Kropf E, Aitken M, Bedoya F, Wolf AI, Erikson J, Caton AJ. Distinct modes of antigen presentation promote the formation, differentiation, and activity of foxp3+ regulatory T cells in vivo. Journal of Immunology (Baltimore, Md. : 1950). 194: 3784-97. PMID 25780041 DOI: 10.4049/Jimmunol.1402960 |
0.37 |
|
| 2013 |
Bedoya F, Cheng GS, Leibow A, Zakhary N, Weissler K, Garcia V, Aitken M, Kropf E, Garlick DS, Wherry EJ, Erikson J, Caton AJ. Viral antigen induces differentiation of Foxp3+ natural regulatory T cells in influenza virus-infected mice. Journal of Immunology (Baltimore, Md. : 1950). 190: 6115-25. PMID 23667113 DOI: 10.4049/Jimmunol.1203302 |
0.39 |
|
| 2009 |
Bedoya F, Medveczky PG. Formation of Mitochondrial Genome Concatemers as an Alternative Mechanism Promoting Oncogenic Transformation of Lymphoid Cells. Bioscience Hypotheses. 2: 310-312. PMID 20046889 DOI: 10.1016/J.Bihy.2009.07.003 |
0.573 |
|
| 2009 |
Bedoya F, Medveczky MM, Lund TC, Perl A, Horvath J, Jett SD, Medveczky PG. Identification of mitochondrial genome concatemers in AIDS-associated lymphomas and lymphoid cell lines. Leukemia Research. 33: 1499-504. PMID 19362738 DOI: 10.1016/J.Leukres.2009.03.012 |
0.573 |
|
| Show low-probability matches. |